Category Archives: TRIPS plus

Seven Decades of Grappling With Intellectual Property Issues in India

Create, Copy, Disrupt: India’s Intellectual Property Dilemmas is well-researched and easy to read, especially for a non-legal audience. By Jayashree Watal, The Wire The book Create, Copy, Disrupt: India’s Intellectual Property Dilemmas (OUP, 2017) is a serious effort by two legal scholars, Prashant … Continue reading

Posted in IPR, TRIPS, TRIPS flexibilities, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

India grants Pfizer patent for pneumonia vaccine

Source: Live Mint India has granted Pfizer a patent for Prevnar 13 pneumonia vaccine, in spite of opposition from the heath group Médecins Sans Frontières (MSF) New Delhi: India has granted US pharmaceutical company Pfizer Inc. a patent for its pneumonia … Continue reading

Posted in Evergreening, Indian Patent Law, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Indian patent for Pfizer’s pneumonia vaccine seen as a blow to aid group

Source: The HinduBusinessLine MUMBAI, AUGUST 22:   The grant of an Indian patent to Pfizer’s Prevenar13, a pneumococcal conjugate vaccine, has raised the hackles of pro-health group MSF who are worried that it will hamper access to the vaccine. “It’s unfair … Continue reading

Posted in Evergreening, Indian Patent Law, Patent, Patent Opposition, Uncategorized, Vaccines | Leave a comment

Draft Pharmaceutical Policy, 2017

Source: All India Drug Action Network (AIDAN) The Department of Pharmaceuticals has circulated a Draft Pharmaceutical Policy, 2017 which can be accessed here. The draft policy identifies the following key objectives: a. Making essential drugs accessible at affordable prices to the … Continue reading

Posted in API, Biologics/Biosimilars, Evergreening, Innovation, IPR, Patent, R&D, Uncategorized | Leave a comment

South African IP policy draft released seeking comments from public

International Trade and Economic Development division of South African Government has released the  Draft Intellectual Property Policy of the Republic of south Africa Phase 2017 and it is now publicly available for comments.  Access the draft policy here: http://www.dti.gov.za/gazzettes/IP_Policy.pdf   

Posted in IPR, R&D, TRIPS, TRIPS flexibilities, TRIPS plus, Uncategorized | Leave a comment

Stakeholder Intervention at 19th RCEP negotiations round- Chalermsak Kittitrakul, network of PLHIV & AIDS, Peoples’ Health Systems Movement, and FTA Watch

Thai CSOs’ comments on the data exclusivity measure in the RCEP given at the stakeholder consultation meeting hosted by the RCEP trade negotiators at Hyderabad, India on July 25, 2017. Good afternoon, trade negotiators of the ASEAN countries and the … Continue reading

Posted in Data Exclusivity, IPR, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, TRIPS&IP rights, Uncategorized | Leave a comment

What’s at stake in Hyderabad

By Feroz Ali, The Hindu | July 28, 2017 India must counter Japan’s U.S.-style pressure at the RCEP talks and ensure affordable generic medicines Leaked texts are like leaked gases — you may never find the one responsible for it, … Continue reading

Posted in Data Exclusivity, IP Rights, IPR, Patent, Patent Term Extension, Regional Comprehensive Economic Partnership, TRIPS, TRIPS plus, Uncategorized | Leave a comment